Pharmacological modulation of Glo-1 as well as silencing of RAGE have shown promise in preclinical models of CCl4-induced liver fibrosis and hepatocellular carcinoma, respectively [9]. The gene discussed is GLO1; the disease is Hepatic fibrosis.